Pediatric Psychopharmacology for Primary Care xv ■■ Medications that have FDA approval for the patient’s diagnosis (or a similar diagnosis) are recommended, whenever possible, because these medications have met a formal standard for efficacy and safety and, generally, more information is available regarding their use in youth. ■■ There are only a few classes of medications (eg, stimulants, α 2 -adrenergic agonists, and selective serotonin reuptake inhibitors) that need to be mastered to effectively treat most presentations of ADHD, common anxiety disorders, and depression. ■■ Providing clinical and medico-legal informed consent and assent can strengthen the therapeutic alliance with patients and caregivers. ■■ Prescribing as few psychotropic medications as possible is recommended to improve safety. ■■ Sequential, not simultaneous, changes in medication are preferred, when- ever possible. ■■ Monitoring for safety is as important as monitoring for effectiveness. ■■ Use of pragmatic supports can improve efficiency and effectiveness. ■■ Resources included in this book are derived from the FDA as well as national organizations such as the AAP and the American Academy of Child and Adolescent Psychiatry. ■■ As an important component of the continuum of mental health care, pediatric PCCs will encounter children who require additional specialty care. Consultative and collaborative relationships with mental health professionals are thus important. What About the Future? ■■ The conceptual framework and treatment strategies in Pediatric Psychopharmacology for Primary Care are designed to prepare pediatric PCCs for future developments in pediatric psychopharmacology and clinical care of children with common psychiatric disorders. New infor- mation about the safety and efficacy of existing psychopharmacologic agents continues to accrue, and safer and more effective medications for children and adolescents will be developed and disseminated. Based on its recent emphasis on pediatric mental health, we can anticipate that the AAP and other professional organizations will provide ongoing and up-to-date educational and training opportunities for interested clinicians (see Appendix C, Training Resources for Clinicians).
Previous Page Next Page